메뉴 건너뛰기




Volumn 95, Issue 1, 2014, Pages 95-104

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells

Author keywords

Mastocytosis; Mcl 1; Targeted therapy

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; DASATINIB; MESSENGER RNA; MIDOSTAURIN; OBATOCLAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; MCL1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MYELOID LEUKEMIA FACTOR 1; ONCOPROTEIN; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL X; PYRROLE DERIVATIVE;

EID: 84897019340     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.1112609     Document Type: Article
Times cited : (31)

References (53)
  • 2
    • 34250796815 scopus 로고    scopus 로고
    • Mastocytosis: State of the art
    • Horny, H. P., Sotlar, K., Valent, P. (2007) Mastocytosis: state of the art. Pathobiology 74, 121-132.
    • (2007) Pathobiology , vol.74 , pp. 121-132
    • Horny, H.P.1    Sotlar, K.2    Valent, P.3
  • 4
    • 51649115383 scopus 로고    scopus 로고
    • Mast cells and mastocytosis
    • Metcalfe, D. D. (2008) Mast cells and mastocytosis. Blood 112, 46-56.
    • (2008) Blood , vol.112 , pp. 46-56
    • Metcalfe, D.D.1
  • 5
    • 77955642537 scopus 로고    scopus 로고
    • Pathogenesis, classification and treatment of mastocytosis: State of the art in 2010 and future perspectives
    • Arock, M., Valent, P. (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev. Hematol. 3, 497-516.
    • (2010) Expert Rev. Hematol. , vol.3 , pp. 497-516
    • Arock, M.1    Valent, P.2
  • 10
    • 0345772088 scopus 로고    scopus 로고
    • Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria
    • Valent, P., Akin, C., Sperr, W. R., Escribano, L., Arock, M., Horny, H. P., Bennett, J. M., Metcalfe, D. D. (2003) Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk. Res. 27, 635-641.
    • (2003) Leuk. Res. , vol.27 , pp. 635-641
    • Valent, P.1    Akin, C.2    Sperr, W.R.3    Escribano, L.4    Arock, M.5    Horny, H.P.6    Bennett, J.M.7    Metcalfe, D.D.8
  • 11
    • 33747336257 scopus 로고    scopus 로고
    • KIT mutations in mastocytosis and their potential as therapeutic targets
    • Gotlib, J. (2006) KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol. Allergy Clin. North Am. 26, 575-592.
    • (2006) Immunol. Allergy Clin. North Am. , vol.26 , pp. 575-592
    • Gotlib, J.1
  • 12
    • 0028856070 scopus 로고
    • Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
    • Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., Metcalfe, D. D. (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92, 10560-10564.
    • (1995) Proc. Natl. Acad. Sci. USA , vol.92 , pp. 10560-10564
    • Nagata, H.1    Worobec, A.S.2    Oh, C.K.3    Chowdhury, B.A.4    Tannenbaum, S.5    Suzuki, Y.6    Metcalfe, D.D.7
  • 13
    • 0009013631 scopus 로고    scopus 로고
    • Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
    • Longley, B. J., Tyrrell, L., Lu, S. Z., Ma, Y. S., Langley, K., Ding, T. G., Duffy, T., Jacobs, P., Tang, L. H., Modlin, I. (1996) Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12, 312-314.
    • (1996) Nat. Genet. , vol.12 , pp. 312-314
    • Longley, B.J.1    Tyrrell, L.2    Lu, S.Z.3    Ma, Y.S.4    Langley, K.5    Ding, T.G.6    Duffy, T.7    Jacobs, P.8    Tang, L.H.9    Modlin, I.10
  • 14
    • 0035010149 scopus 로고    scopus 로고
    • Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis
    • Fritsche-Polanz, R., Jordan, J. H., Feix, A., Sperr, W. R., Sunder-Plassmann, G., Valent, P., Födinger, M. (2001) Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 113, 357-364.
    • (2001) Br. J. Haematol. , vol.113 , pp. 357-364
    • Fritsche-Polanz, R.1    Jordan, J.H.2    Feix, A.3    Sperr, W.R.4    Sunder-Plassmann, G.5    Valent, P.6    Födinger, M.7
  • 15
    • 0027359443 scopus 로고
    • IdentifIication of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product
    • Furitsu, T., Tsujimura, T., Tono, T., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J. H., Ashman, L. K., Kanayama, Y. (1993) IdentifIication of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J. Clin. Invest. 92, 1736-1744.
    • (1993) J. Clin. Invest. , vol.92 , pp. 1736-1744
    • Furitsu, T.1    Tsujimura, T.2    Tono, T.3    Kitayama, H.4    Koshimizu, U.5    Sugahara, H.6    Butterfield, J.H.7    Ashman, L.K.8    Kanayama, Y.9
  • 17
    • 22144455380 scopus 로고    scopus 로고
    • Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412
    • Growney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., Gilliland, D. G. (2005) Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106, 721-724.
    • (2005) Blood , vol.106 , pp. 721-724
    • Growney, J.D.1    Clark, J.J.2    Adelsperger, J.3    Stone, R.4    Fabbro, D.5    Griffin, J.D.6    Gilliland, D.G.7
  • 19
    • 26944458584 scopus 로고    scopus 로고
    • The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107
    • Von Bubnoff, N., Gorantla, S. H., Kancha, R. K., Lordick, F., Peschel, C., Duyster, J. (2005) The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 19, 1670-1671.
    • (2005) Leukemia , vol.19 , pp. 1670-1671
    • Von Bubnoff, N.1    Gorantla, S.H.2    Kancha, R.K.3    Lordick, F.4    Peschel, C.5    Duyster, J.6
  • 20
    • 30444446680 scopus 로고    scopus 로고
    • The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: Comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects
    • Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., Valent, P. (2006) The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood 107, 752-759.
    • (2006) Blood , vol.107 , pp. 752-759
    • Gleixner, K.V.1    Mayerhofer, M.2    Aichberger, K.J.3    Derdak, S.4    Sonneck, K.5    Böhm, A.6    Gruze, A.7    Samorapoompichit, P.8    Manley, P.W.9    Fabbro, D.10    Pickl, W.F.11    Sillaber, C.12    Valent, P.13
  • 21
    • 31544459272 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
    • Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D., Lee, F. Y., Bokemeyer, C., Deininger, M. W., Druker, B. J., Heinrich, M. C. (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66, 473-481.
    • (2006) Cancer Res. , vol.66 , pp. 473-481
    • Schittenhelm, M.M.1    Shiraga, S.2    Schroeder, A.3    Corbin, A.S.4    Griffith, D.5    Lee, F.Y.6    Bokemeyer, C.7    Deininger, M.W.8    Druker, B.J.9    Heinrich, M.C.10
  • 22
    • 33645687784 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
    • Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., Akin, C. (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 108, 286-291.
    • (2006) Blood , vol.108 , pp. 286-291
    • Shah, N.P.1    Lee, F.Y.2    Luo, R.3    Jiang, Y.4    Donker, M.5    Akin, C.6
  • 26
    • 79960404044 scopus 로고    scopus 로고
    • KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: Report of fully accrued phase II trial
    • Gotlib, J., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., Dutreix, C., Gross, S., Nikolova, Z., Graubert, T. (2010) KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of fully accrued phase II trial. Blood 116, 144.
    • (2010) Blood , vol.116 , pp. 144
    • Gotlib, J.1    DeAngelo, D.J.2    George, T.I.3    Corless, C.L.4    Linder, A.5    Langford, C.6    Dutreix, C.7    Gross, S.8    Nikolova, Z.9    Graubert, T.10
  • 28
    • 33745042240 scopus 로고    scopus 로고
    • Pathogenesis, clinical features, and treatment advances in mastocytosis
    • Pardanani, A., Akin, C., Valent, P. (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract. Res. Clin. Haematol. 19, 595-615.
    • (2006) Best Pract. Res. Clin. Haematol. , vol.19 , pp. 595-615
    • Pardanani, A.1    Akin, C.2    Valent, P.3
  • 34
    • 33947579975 scopus 로고    scopus 로고
    • Identification of MCL-1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL-1 antisense oligonucleotides and synergism with PKC412
    • Aichberger, K. J., Mayerhofer, M., Gleixner, K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Müllauer, L., Agis, H., Sillaber, C., Valent, P. (2007) Identification of MCL-1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL-1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041.
    • (2007) Blood , vol.109 , pp. 3031-3041
    • Aichberger, K.J.1    Mayerhofer, M.2    Gleixner, K.V.3    Krauth, M.T.4    Gruze, A.5    Pickl, W.F.6    Wacheck, V.7    Selzer, E.8    Müllauer, L.9    Agis, H.10    Sillaber, C.11    Valent, P.12
  • 35
    • 34249982915 scopus 로고    scopus 로고
    • Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
    • Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., Stewart, A. K. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438.
    • (2007) Blood , vol.109 , pp. 5430-5438
    • Trudel, S.1    Li, Z.H.2    Rauw, J.3    Tiedemann, R.E.4    Wen, X.Y.5    Stewart, A.K.6
  • 37
    • 58149168589 scopus 로고    scopus 로고
    • Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy
    • Azmi, A. S., Mohammad, R. M. (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell. Physiol. 218, 13-21.
    • (2009) J. Cell. Physiol. , vol.218 , pp. 13-21
    • Azmi, A.S.1    Mohammad, R.M.2
  • 39
    • 0023950976 scopus 로고
    • Establishment of an immature mast cell line from a patient with mast cell leukemia
    • Butterfield, J. H., Weiler, D., Dewald, G., Gleich, G. J. (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk. Res. 12, 345-355.
    • (1988) Leuk. Res. , vol.12 , pp. 345-355
    • Butterfield, J.H.1    Weiler, D.2    Dewald, G.3    Gleich, G.J.4
  • 40
    • 0033956308 scopus 로고    scopus 로고
    • Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
    • Akin, C., Kirshenbaum, A. S., Semere, T., Worobec, A. S., Scott, L. M., Metcalfe, D. D. (2000) Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28, 140-147.
    • (2000) Exp. Hematol. , vol.28 , pp. 140-147
    • Akin, C.1    Kirshenbaum, A.S.2    Semere, T.3    Worobec, A.S.4    Scott, L.M.5    Metcalfe, D.D.6
  • 42
    • 0037046801 scopus 로고    scopus 로고
    • Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts
    • Dolznig, H., Habermann, B., Stangl, K., Deiner, E. M., Moriggl, R., Beug, H., Müllner, E. W. (2002) Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr. Biol. 12, 1076-1085.
    • (2002) Curr. Biol. , vol.12 , pp. 1076-1085
    • Dolznig, H.1    Habermann, B.2    Stangl, K.3    Deiner, E.M.4    Moriggl, R.5    Beug, H.6    Müllner, E.W.7
  • 43
    • 0025514349 scopus 로고
    • Establishment of two dog mastocytoma cell lines in continuous culture
    • DeVinney, R., Gold, W. M. (1990) Establishment of two dog mastocytoma cell lines in continuous culture. Am. J. Respir. Cell Mol. Biol. 3, 413-420.
    • (1990) Am. J. Respir. Cell Mol. Biol. , vol.3 , pp. 413-420
    • DeVinney, R.1    Gold, W.M.2
  • 44
    • 0024381556 scopus 로고
    • Mast cell typing: Demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes
    • Valent, P., Ashman, L. K., Hinterberger, W., Eckersberger, F., Majdic, O., Lechner, K., Bettelheim, P. (1989) Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. Blood 73, 1778-1785.
    • (1989) Blood , vol.73 , pp. 1778-1785
    • Valent, P.1    Ashman, L.K.2    Hinterberger, W.3    Eckersberger, F.4    Majdic, O.5    Lechner, K.6    Bettelheim, P.7
  • 46
    • 0036373335 scopus 로고    scopus 로고
    • Morphological and biochemical aspects of apoptosis, oncosis and necrosis
    • Van Cruchten, S., van Den Broeck, W. (2002) Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat. Histol. Embryol. 31, 214-223.
    • (2002) Anat. Histol. Embryol. , vol.31 , pp. 214-223
    • Van Cruchten, S.1    van Den Broeck, W.2
  • 49
    • 84862737555 scopus 로고    scopus 로고
    • Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
    • Rahmani, M., Aust, M. M., Attkisson, E., Williams, D. C. Jr., Ferreira-Gonzalez, A., Grant, S. (2012) Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood 119, 6089-6098.
    • (2012) Blood , vol.119 , pp. 6089-6098
    • Rahmani, M.1    Aust, M.M.2    Attkisson, E.3    Williams Jr., D.C.4    Ferreira-Gonzalez, A.5    Grant, S.6
  • 50
    • 53349097246 scopus 로고    scopus 로고
    • BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis
    • Mott, J. L., Bronk, S. F., Mesa, R. A., Kaufmann, S. H., Gores, G. J. (2008) BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther. 7, 2339-2347.
    • (2008) Mol. Cancer Ther. , vol.7 , pp. 2339-2347
    • Mott, J.L.1    Bronk, S.F.2    Mesa, R.A.3    Kaufmann, S.H.4    Gores, G.J.5
  • 51
    • 36048986227 scopus 로고    scopus 로고
    • The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells
    • Ekoff, M., Kaufmann, T., Engström, M., Motoyama, N., Villunger, A., Jönsson, J. I., Strasser, A., Nilsson, G. (2007) The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110, 3209-3217.
    • (2007) Blood , vol.110 , pp. 3209-3217
    • Ekoff, M.1    Kaufmann, T.2    Engström, M.3    Motoyama, N.4    Villunger, A.5    Jönsson, J.I.6    Strasser, A.7    Nilsson, G.8
  • 52
    • 80051475544 scopus 로고    scopus 로고
    • Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
    • Ustun, C., DeRemer, D. L., Akin, C. (2011) Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk. Res. 35, 1143-1152.
    • (2011) Leuk. Res. , vol.35 , pp. 1143-1152
    • Ustun, C.1    DeRemer, D.L.2    Akin, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.